Smoking Cessation Using Motivational Therapy and Varenicline
| Status: | Completed |
|---|---|
| Conditions: | Smoking Cessation, HIV / AIDS |
| Therapuetic Areas: | Immunology / Infectious Diseases, Pulmonary / Respiratory Diseases |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 4/13/2015 |
| Start Date: | June 2008 |
| End Date: | June 2013 |
| Contact: | Philip T. T. Diaz, MD |
| Email: | philip.diaz@osumc.edu |
| Phone: | 614-293-4978 |
Smoking Cessation and the Natural History of HIV-Associated Emphysema
People that are infected with HIV appear to be especially susceptible to the adverse effects
of cigarette smoking. The purpose of this study is to determine if quitting smoking by
using a specialized smoking cessation treatment can prevent one from developing accelerated
lung damage, particularly emphysema.
of cigarette smoking. The purpose of this study is to determine if quitting smoking by
using a specialized smoking cessation treatment can prevent one from developing accelerated
lung damage, particularly emphysema.
HIV-infected smokers are at increased risk for life-threatening diseases, such as pneumonia.
To date, very little is known about the tobacco consumption characteristics of this at-risk
population of smokers, but it has been well documented that they are at high risk for
smoking-related co-morbidities. In addition, few effective cessation strategies have been
described in HIV-infected populations. A specialized smoking cessation that combines
recommendations from an existing scientifically-valid clinical guideline with Motivational
Interviewing a new pharmacotherapeutic agent, may be an effective mechanism to apply to this
vulnerable population of smokers. This initial, efficacy investigation has the potential to
guide future treatment and research pertaining to tobacco cessation, respiratory illness and
HIV.
To date, very little is known about the tobacco consumption characteristics of this at-risk
population of smokers, but it has been well documented that they are at high risk for
smoking-related co-morbidities. In addition, few effective cessation strategies have been
described in HIV-infected populations. A specialized smoking cessation that combines
recommendations from an existing scientifically-valid clinical guideline with Motivational
Interviewing a new pharmacotherapeutic agent, may be an effective mechanism to apply to this
vulnerable population of smokers. This initial, efficacy investigation has the potential to
guide future treatment and research pertaining to tobacco cessation, respiratory illness and
HIV.
Inclusion Criteria:
1. 18 years of age and older;
2. diagnosis of HIV;
3. self-reported smoking on a daily basis;
4. provide informed written consent
Exclusion Criteria:
1. persons with active psychosis or impaired mental status as judged by the clinic staff
and confirmed with a Mini-Mental Status Exam)
2. unable to understand spoken English
3. age less than 18 years.
4. pregnant women
We found this trial at
1
site
Ohio State University The Ohio State University’s main Columbus campus is one of America’s largest...
Click here to add this to my saved trials
